Meeting
2016 ASCO Annual Meeting
A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.
Authors
Keun Wook Lee
Seoul National University Bundang Hosp, Seoul National University College of Medicine, Seongnam-Si, Korea South
Keun Wook Lee , Do-Youn Oh , Sae-Won Han , Jin Won Kim , Jung-Won Shin , Seong-Jin Jo , Na Hyung Kim , Ahmi Woo , Jonghwa Won , Seokyung Hahn , Howard Lee , Woo Ho Kim , Yung-Jue Bang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Antibodies
Clinical Trial Registration Number
NCT02352571
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2521)
DOI
10.1200/JCO.2016.34.15_suppl.2521
Abstract #
2521
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
First Author: R. Dienstmann
Poster
2022 ASCO Annual Meeting
The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.
First Author: Anthony B. El-Khoueiry
Poster
2017 Gastrointestinal Cancers Symposium
Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.
First Author: Amy E. Chang
Poster
2016 ASCO Annual Meeting
Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.
First Author: Ken Kato